



مختبر فرايبورج الطبي الشرق الأوسط (ذ.م.م.)
FREIBURG MEDICAL LABORATORY MIDDLE EAST (L.L.C.)

Prostate Health Index: A New Test for the Detection of Prostate Cancer (PHI)

A major focus in urologic research is the identification of new biomarkers with improved specificity for clinically significant prostate cancers. A promising new test, based on prostate-specific antigen (PSA), is called the Prostate Health Index (PHI), which has recently been approved in the United States, Europe and Australia. PHI is a mathematical formula that combines total PSA, free PSA and [-2] proPSA. Numerous international studies have consistently shown that PHI outperforms its individual components for the prediction of overall and high-grade prostate cancer on biopsy. PHI also predicts the likelihood of progression during active surveillance, providing another non-invasive modality to potentially select and monitor this patient population.

Source: Stacy Loeb and William J. Catalona: TherAdv Urol. 2014 Apr; 6(2): 74–77

Indication: prediction of overall and high-grade prostate cancer, prediction of the likelihood of progression during active surveillance
Material: 2 ml serum
Turnaround time: Germany, 5-7 d
Method: CLIA